Navigation Links
Promising new treatment option for women with recurrent ovarian cancer
Date:9/15/2008

Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

The combination, which importantly does not include a platinum drug, challenges the current standard of treatment for women whose cancer recurs at least 6 months after first-line treatment, said Associate Prof. Bradley J. Monk from the University of California Irvine Medical Center.

"This trial, which included almost two-thirds such women, challenges this traditional paradigm and suggests that a non-platinum doublet is also effective in this setting," he said. "Trabectedin represents a 'new chemical entity' in North America and if approved by the FDA, would be an important new option for women with recurrent ovarian cancer."

Trabectedin, a synthetic version of a compound first isolated from sea-squirts, has been granted marketing approval in Europe for the treatment of patients with advanced soft tissue sarcoma.

In the latest trial, an international group of researchers studied the combination in 672 women whose ovarian cancer had progressed after first-line therapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus trabectedin 1.1mg/m2 over 3 hours every 3 weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks.

The median length of progression-free survival for women on the combination therapy was 7.3 months, the researchers found, compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free survival time was 9.2 months for the combination treatment, compared to 7.5 months for patients in the other arm.

"This drug appears active in all sub-groups included in the trial, but lik
'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... which trauma and burn patients are most likely to ... range of experimental clinical settings ?an important hurdle to ... rooms and intensive care units. , In a report ... National Academy of Sciences, researchers from eight institutions, including ...
... of California, San Diego (UCSD) have found that Lafora disease, ... the age of 30, can be caused by mutations in ... These findings are reported in the current issue of Proceedings ... is characterized by normal development for the first decade of ...
... comparing, for the first time, breast cancers from Nigeria, ... African ancestry are more likely to be diagnosed with ... of European ancestry. , Researchers from the University of ... in Nigeria and the University of North Carolina, found ...
Cached Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
(Date:8/31/2015)... BALTIMORE , Aug. 31, 2015  For people ... may brighten their day. The biotechnology company, located in ... outlined one of the best potential therapies yet for ... paper entitled, " Correction of Down syndrome and Edwards ... the journal DNA Research . Elixirgen plans to ...
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
(Date:8/30/2015)... , England , August 31, ... beendet die 51-jährige Wartezeit   einer Frau   für ... Frauen im Alter von 7-90   werden ... Programm soll 1200 Frauen behandeln und die ... , Astellas gab heute bekannt, ...
Breaking Biology Technology:New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... Colo., Sept. 25 Steve Pettit, Director of,the ... http://www.InVitria.com ) Cellastim in mammalian cell culture at ... week., "Cellastim showed superior results compared to ... 50% improvement in productivity in CHO cell,lines using ...
... in Complement Inhibition and,Impact of Soliris on Patients ... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) has ... Biotechnology Product for Soliris(R) (eculizumab). The Award,recognizes the ... and the impact the drug is,having on the ...
... Net Income of $27 to $28 ... ... Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), ... China ("PRC"), today announced that it,has increased its revenue and earnings guidance ...
Cached Biology Technology:InVitria's Cellastim Delivers Superior Results in Mammalian Cell Culture 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 2China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 3
...
... Suite for Mac OS X provides the ... and protein sequence analysis and molecular biology ... (Table 1). With Vector NTI Suite you ... and publicize diverse types of molecular biology ...
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Biology Products: